{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:34:46Z","timestamp":1790678086150,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.bone.2022.116647","type":"journal-article","created":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T17:21:08Z","timestamp":1671384068000},"page":"116647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Cardiac adverse events in bisphosphonate and teriparatide users: An international pharmacovigilance study"],"prefix":"10.1016","volume":"168","author":[{"given":"Alexander J.","family":"Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitesh","family":"Nerlekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Ebeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9757","key":"10.1016\/j.bone.2022.116647_bb0005","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.bone.2022.116647_bb0010","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"HORIZON pivotal fracture trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.bone.2022.116647_bb0015","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"5\u20136","key":"10.1016\/j.bone.2022.116647_bb0020","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.vph.2009.09.002","article-title":"Alendronate affects calcium dynamics in cardiomyocytes in vitro","volume":"51","author":"Kemeny-Suss","year":"2009","journal-title":"Vascul. Pharmacol."},{"issue":"1","key":"10.1016\/j.bone.2022.116647_bb0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jbmr.3860","article-title":"Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women","volume":"35","author":"Reid","year":"2020","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2022.116647_bb0030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijcard.2009.11.041","article-title":"Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis","volume":"142","author":"Bhuriya","year":"2010","journal-title":"Int. J. Cardiol."},{"issue":"4","key":"10.1016\/j.bone.2022.116647_bb0035","article-title":"Bisphosphonates and risk of cardiovascular events: A meta-analysis","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS ONE [Internet]"},{"issue":"11","key":"10.1016\/j.bone.2022.116647_bb0040","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.amjcard.2014.03.008","article-title":"Risk of atrial fibrillation with use of oral and intravenous bisphosphonates","volume":"113","author":"Sharma","year":"2014","journal-title":"Am. J. Cardiol."},{"issue":"18","key":"10.1016\/j.bone.2022.116647_bb0045","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","article-title":"Fracture risk and zoledronic acid therapy in men with osteoporosis","volume":"367","author":"Boonen","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.bone.2022.116647_bb0050","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJMc076132","article-title":"Alendronate and atrial fibrillation","volume":"356","author":"Cummings","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bone.2022.116647_bb0055","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00198-011-1546-9","article-title":"Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials","volume":"23","author":"Barrett-Connor","year":"2012","journal-title":"Osteoporos. Int. J. Establ. Result Coop. Eur. Found. Osteoporos. Natl. Osteoporos. Found. USA"},{"issue":"4","key":"10.1016\/j.bone.2022.116647_bb0060","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/1074248420984082","article-title":"Use of disproportionality analysis to identify previously unknown drug-associated causes of cardiac arrhythmias using the Food and Drug Administration adverse event reporting system (FAERS) database","volume":"26","author":"Moreland-Head","year":"2021","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.bone.2022.116647_bb0065","doi-asserted-by":"crossref","DOI":"10.5603\/EP.a2021.0044","article-title":"Atrial electromechanical delay is impaired in patients with primary hyperparathyroidism","author":"Kele\u015fo\u011flu","year":"2021","journal-title":"Endokrynol. Pol."},{"issue":"11","key":"10.1016\/j.bone.2022.116647_bb0070","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa450","article-title":"Cardiovascular safety of abaloparatide in postmenopausal women with osteoporosis: analysis from the ACTIVE phase 3 trial","volume":"105","author":"Cosman","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.bone.2022.116647_bb0075","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inf. J. DIJ Drug Inf. Assoc."},{"issue":"8","key":"10.1016\/j.bone.2022.116647_bb0080","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"4","key":"10.1016\/j.bone.2022.116647_bb0085","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bone.2022.116647_bb0090","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0962280211403604","article-title":"Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery","volume":"22","author":"Nor\u00e9n","year":"2013","journal-title":"Stat. Methods Med. Res."},{"issue":"12","key":"10.1016\/j.bone.2022.116647_bb0095","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.bone.2022.116647_bb0100","first-page":"1","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"issue":"43","key":"10.1016\/j.bone.2022.116647_bb0105","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J. Open Source Softw."},{"issue":"10","key":"10.1016\/j.bone.2022.116647_bb0110","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1056\/NEJM199809033391003","article-title":"Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins","volume":"339","author":"Ha\u00efssaguerre","year":"1998","journal-title":"N. Engl. J. Med. Massachusetts Medical Society"},{"key":"10.1016\/j.bone.2022.116647_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115296","article-title":"Cardiovascular and skeletal safety of zoledronic acid in osteoporosis observational, matched cohort study using danish and Swedish health registries","volume":"134","author":"Rubin","year":"2020","journal-title":"Bone"},{"issue":"10","key":"10.1016\/j.bone.2022.116647_bb0120","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa481","article-title":"Oral bisphosphonate use reduces cardiovascular events in a cohort of danish patients referred for bone mineral density","volume":"105","author":"Rodr\u00edguez","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.bone.2022.116647_bb0125","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1530\/EJE-20-0650","article-title":"Atrial fibrillation in patients treated with intravenous zoledronic or pamidronic acid: a pharmacoepidemiological study","volume":"184","author":"Pijnenburg","year":"2021","journal-title":"Eur. J. Endocrinol."},{"issue":"27","key":"10.1016\/j.bone.2022.116647_bb0130","article-title":"A single-center prospective study of 116 women with osteoporosis treated with zoledronic acid monitored by electrocardiography for the development of cardiac arrhythmia during the acute phase in China","volume":"12","author":"Zhuang","year":"2021","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"issue":"25","key":"10.1016\/j.bone.2022.116647_bb0135","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture prevention with zoledronate in older women with osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bone.2022.116647_bb0140","doi-asserted-by":"crossref","first-page":"130","DOI":"10.18773\/austprescr.2000.144","article-title":"Experimental and clinical pharmacology: bisphosphonates - mechanisms of action","volume":"23","author":"Martin","year":"2000","journal-title":"Aust. Prescr. NPS MedicineWise"},{"issue":"8","key":"10.1016\/j.bone.2022.116647_bb0145","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/jbmr.3448","article-title":"Association of Alendronate and Risk of cardiovascular events in patients with hip fracture","volume":"33","author":"Sing","year":"2018","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"issue":"19","key":"10.1016\/j.bone.2022.116647_bb0150","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N. Engl. J. Med."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328222003246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328222003246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:03:39Z","timestamp":1757613819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328222003246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":30,"alternative-id":["S8756328222003246"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2022.116647","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac adverse events in bisphosphonate and teriparatide users: An international pharmacovigilance study","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2022.116647","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116647"}}